The generic cancer drug shortage can be fixed — yet there doesn't seem to be much sense of urgency to fix the problem.June 20, 2023Check out STAT+Sponsored By Adobe Opinion: Cancer drug shortages should have patients rioting in the streets Cisplatin and carboplatin are the backbone for lung cancer regimens because they work. And now they are largely unavailable. By Kristen Rice STAT+ | Opinion: The DNA from dog tumors may hold the secret to better human cancer drugs As the cost of genetic sequencing continues to plummet, we can no longer afford to ignore this vital tool in our fight against cancer. By Christina Lopes and James Zou Opinion: What happens when patients beat their doctors to their test results Any and all clinical information must be made immediately available to patients once it is finalized. Too often, that makes my patients panic. By Christopher Medrano More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments